Stock Price Quote

DR AGARWALS EYE HOSPITAL LTD.

NSE : NABSE : 526783ISIN CODE : INE934C01018Industry : Hospital & Healthcare ServicesHouse : Private
BSE5496.95-69.8 (-1.25 %)
PREV CLOSE ( ) 5566.75
OPEN PRICE ( ) 5550.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1202
TODAY'S LOW / HIGH ( )5450.00 5601.95
52 WK LOW / HIGH ( ) 35007300
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 22-04 1994
Management Info
Amar Agarwal - Chairman Amar Agarwal - Managing Director
Registered Office

Address 3rd Floor, Buhari Towers, No.4, Moores Road,Off. Greams Road,Near Asan Memorial School,
Chennai,
Tamil Nadu-600006

Phone 044-43787777 / 78

Email info@dragarwal.com

Website www.dragarwal.com

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai
Listing : BSE

NEWS

27Oct Dr. Agarwal’s Eye Hospital informs abo
In furtherance to letter dated October 22, 2025, Dr. Agarwal’s Eye Hospi..
19Mar Dr Agarwals Eye Hospital commences ope
Dr Agarwals Eye Hospital has commenced operation of a new branch located..
30Sep Dr. Agarwal’s Eye Hospital informs abo
As per the SEBI (Prohibition of Insider Trading) Regulations, 2015 and t..
28Sep Dr.Agarwals Eye Hospital informs about
Dr.Agarwals Eye Hospital has informed that the Exchange has received Dis..
23Sep Dr. Agarwal’s Eye Hospital informs abo
Pursuant to Regulation 30 read with Para B of Part A of Schedule III of..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit193.2546.5
Gross Profit 257.2 707
Operating Profit 407.61235.9
Net Sales 1177.23971.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kovai Medical Center (BSE)
peergroup  5915.30 (2.31%)
M.Cap ( in Cr)6472.68
Vijaya Diagnostic (BSE)
peergroup  1078.65 (7.36%)
M.Cap ( in Cr)34098.15
Dr. Lal Pathlabs (BSE)
peergroup  3054.45 (1.94%)
M.Cap ( in Cr)25588.81
Apollo Hospital Ent. (BSE)
peergroup  7198.35 (0.27%)
M.Cap ( in Cr)103501.23
Sharma Hospitals (BSE)
peergroup  136.85 (4.55%)
M.Cap ( in Cr)44.94

Shareholding Pattern

PROMOTERS 72.67%
NON-INSTITUTION 23.23%
MUTUAL FUNDS/UTI 0.18%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Dr Agarwals Eye Hospital Ltd.

Dr Agarwals Eye Hospital Ltd. was incorporated in the year 1994. Its today's share price is 5496.95. Its current market capitalisation stands at Rs 2656.58 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3971.5 Cr and Total Income of Rs.4029.6 Cr. The company's management includes Adil Agarwal, Shiv Agrawal, Latha Ramanathan, Balakrishnan Venkatraman, Athiya Agarwal, Amar Agarwal, Amar Agarwal, Meenakshi Jayaraman.

It is listed on the BSE with a BSE Code of 526783 , NSE with an NSE Symbol of and ISIN of INE934C01018. It's Registered office is at 3rd Floor, Buhari Towers, No.4, Moores Road,Off. Greams Road,Near Asan Memorial SchoolChennai-600006, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, MK Dandekar & Co, MK Dandeker & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.